Analysts expect that The Medicines Company (NASDAQ:MDCO) will report earnings of ($0.48) per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for The Medicines’ earnings, with the lowest EPS estimate coming in at ($0.65) and the highest estimate coming in at ($0.28). The Medicines posted earnings per share of ($0.42) in the same quarter last year, which suggests a negative year over year growth rate of 14.3%. The firm is scheduled to report its next earnings results on Wednesday, October 24th.
On average, analysts expect that The Medicines will report full year earnings of ($2.28) per share for the current year, with EPS estimates ranging from ($2.58) to ($1.97). For the next fiscal year, analysts expect that the firm will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.42) to ($0.94). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover The Medicines.
The Medicines (NASDAQ:MDCO) last posted its earnings results on Wednesday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.00) by $0.30. The company had revenue of $1.67 million for the quarter, compared to analysts’ expectations of $7.20 million. The Medicines had a negative return on equity of 394.33% and a negative net margin of 668.93%. The Medicines’s quarterly revenue was down 84.6% on a year-over-year basis. During the same period last year, the firm earned ($0.72) earnings per share.
Shares of NASDAQ MDCO traded up $0.22 during trading hours on Friday, hitting $29.91. The company’s stock had a trading volume of 1,554,000 shares, compared to its average volume of 1,020,023. The company has a debt-to-equity ratio of 31.23, a current ratio of 2.60 and a quick ratio of 2.55. The stock has a market capitalization of $2.25 billion, a PE ratio of -3.54 and a beta of 0.77. The Medicines has a 12 month low of $24.45 and a 12 month high of $41.57.
In other The Medicines news, CEO Clive Meanwell sold 50,000 shares of The Medicines stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $39.24, for a total transaction of $1,962,000.00. Following the sale, the chief executive officer now directly owns 352,034 shares of the company’s stock, valued at approximately $13,813,814.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 150,000 shares of company stock worth $5,731,000. Insiders own 10.29% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. CIBC Asset Management Inc bought a new stake in The Medicines during the 2nd quarter valued at approximately $210,000. NumerixS Investment Technologies Inc bought a new stake in The Medicines during the 2nd quarter valued at approximately $229,000. Xact Kapitalforvaltning AB boosted its position in The Medicines by 28.9% during the 1st quarter. Xact Kapitalforvaltning AB now owns 10,260 shares of the company’s stock valued at $338,000 after acquiring an additional 2,300 shares in the last quarter. Teza Capital Management LLC bought a new stake in The Medicines during the 1st quarter valued at approximately $342,000. Finally, PNC Financial Services Group Inc. boosted its position in The Medicines by 29.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,545 shares of the company’s stock valued at $348,000 after acquiring an additional 2,398 shares in the last quarter.
The Medicines Company Profile
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Recommended Story: Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.